A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Anthony R. Mato, Stephen J. Schuster, Nicole Lamanna, Ian Flinn, Jacqueline Claudia Barrientos, Suman Kambhampati, Bruce D. Cheson, Paul M. Barr, John M. Pagel, James Andrew Reeves, Frederick Lansigan, Jeffrey J. Pu, Alan P. Skarbnik, Gustavo A. Fonseca, Colleen Dorsey, Eline Luning Prak, Dana Paskalis, Peter Sportelli, Hari P. Miskin, Danielle M. Brander
Institutions: Memorial Sloan Kettering Cancer Center, Abramson Cancer Center, Columbia University Irving Medical Center, Sarah Cannon, Northwell Health, Research Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of Rochester Medicine, Dartmouth–Hitchcock Medical Center, Penn State Cancer Institute, City of Hope, Hospital of the University of Pennsylvania, TG Therapeutics, Inc. (United States), Duke University, Duke Medical Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890142689